Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.94
-0.10 (-1.42%)
At close: Mar 24, 2026, 4:00 PM EDT
6.99
+0.05 (0.72%)
After-hours: Mar 24, 2026, 6:17 PM EDT

Gyre Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
9.8817.9-85.484.31-87.93
Depreciation & Amortization
2.481.551.071.090.29
Stock-Based Compensation
7.160.837.2813.373.41
Other Adjustments
-2.93-8.2395.59-0.29-
Change in Receivables
-11.95-9.291.3-7.921.5
Changes in Inventories
-3.63-2.141.75-0.88-
Changes in Accounts Payable
0.01-0.250.19-0.110.5
Changes in Accrued Expenses
0.95-1.51.451.91-3.68
Changes in Income Taxes Payable
0.04-2.173-1.34-
Changes in Unearned Revenue
-----1.75
Changes in Other Operating Activities
-1-0.36-0.230.543.92
Operating Cash Flow
1.01-3.6425.8910.68-83.76
Operating Cash Flow Growth
--142.50%--
Capital Expenditures
-1.19-2.32-8.52-4.99-0.84
Sale of Property, Plant & Equipment
0.030.40.66--
Purchases of Intangible Assets
-0.73-0.81-0.07-0.01-
Purchases of Investments
-14.01-15.47-15.74-7.48-
Proceeds from Sale of Investments
15.43---49.03
Other Investing Activities
--1.693.9-1.33-
Investing Cash Flow
-0.47-19.88-19.76-13.8148.19
Issuance of Common Stock
25.872.64--49.55
Net Common Stock Issued (Repurchased)
25.872.64--49.55
Issuance of Preferred Stock
--2.5--
Net Preferred Stock Issued (Repurchased)
--2.5--
Other Financing Activities
-1.49-0.54---
Financing Cash Flow
24.382.12.5-49.55
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.34-0.27-0.3-1.89-
Net Cash Flow
25.26-21.78.33-5.0313.99
Free Cash Flow
-0.18-5.9617.385.69-84.59
Free Cash Flow Growth
--205.25%--
FCF Margin
-0.15%-5.63%15.32%5.56%-1152.82%
Free Cash Flow Per Share
-0.00-0.060.260.08-1.27
Levered Free Cash Flow
2.694.92-94.22-1.47-89.49
Unlevered Free Cash Flow
5.535.29-75.950.44-89.46
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q